Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Trial ID or NCT#
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
- - Patients must be at least 12 years of age - Applicable disease criteria - Patients must have one or two partially HLA-matched CBUs - Back-up stem cell source - Sufficient physiological reserves - Females of childbearing potential agree to use appropriate method of contraception - Signed written informed consent
- - Extensive bone marrow fibrosis - Donor specific anti-HLA antibodies - Pregnancy - Medically unsuitable for transplant
Contact us to find out if this trial is right for you.